Gene therapy to improve function of T cells for adoptive immunotherapy.

Concetta Quintarelli, Barbara Savoldo, Gianpietro Dotti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Adoptive immunotherapy with cytotoxic T cells has shown promising clinical results in patients with metastatic melanoma and post-transplant-associated viral infections. However, the antitumor effect of adoptively transferred tumor-specific cytotoxic T lymphocytes (CTLs) is impaired by the limited capacity of these cells to expand within the tumor microenvironment. Administration of interleukin 2 (IL-2) has been used to overcome this limitation, but the systemic toxicity and the expansion of unwanted cells, including regulatory T cells, limit the clinical value of this strategy. To discover whether transgenic expression of lymphokines by the CTLs themselves might overcome these limitations, we evaluated the effects of transgenic expression of IL-2 and IL-15 in our model of Epstein-Barr Virus-specific CTLs (EBV-CTLs). We found that transgenic expression of IL-2 or IL-15 increased the expansion of EBV-CTLs in vitro and that these gene-modified EBV-CTL had enhanced antitumor activity, while maintaining their antigen-specificity. Although the proliferation of these cytokine gene transduced CTLs remained strictly antigen dependent, clinical application of this approach likely requires the inclusion of a suicide gene to deal with the potential development of T-cell mutants with autonomous growth. We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach.

Original languageEnglish
Pages (from-to)119-130
Number of pages12
JournalMethods in molecular biology (Clifton, N.J.)
Volume651
DOIs
Publication statusPublished - 2010

Fingerprint

Adoptive Immunotherapy
Cytotoxic T-Lymphocytes
Genetic Therapy
T-Lymphocytes
Human Herpesvirus 4
Interleukin-2
Interleukin-15
Suicide
Genes
Antigens
Tumor Microenvironment
Caspase 9
Lymphokines
Dimerization
Virus Diseases
Regulatory T-Lymphocytes
Melanoma
Cytokines
Transplants
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gene therapy to improve function of T cells for adoptive immunotherapy. / Quintarelli, Concetta; Savoldo, Barbara; Dotti, Gianpietro.

In: Methods in molecular biology (Clifton, N.J.), Vol. 651, 2010, p. 119-130.

Research output: Contribution to journalArticle

@article{b7fead3e1cf54f049b2037453df3ea42,
title = "Gene therapy to improve function of T cells for adoptive immunotherapy.",
abstract = "Adoptive immunotherapy with cytotoxic T cells has shown promising clinical results in patients with metastatic melanoma and post-transplant-associated viral infections. However, the antitumor effect of adoptively transferred tumor-specific cytotoxic T lymphocytes (CTLs) is impaired by the limited capacity of these cells to expand within the tumor microenvironment. Administration of interleukin 2 (IL-2) has been used to overcome this limitation, but the systemic toxicity and the expansion of unwanted cells, including regulatory T cells, limit the clinical value of this strategy. To discover whether transgenic expression of lymphokines by the CTLs themselves might overcome these limitations, we evaluated the effects of transgenic expression of IL-2 and IL-15 in our model of Epstein-Barr Virus-specific CTLs (EBV-CTLs). We found that transgenic expression of IL-2 or IL-15 increased the expansion of EBV-CTLs in vitro and that these gene-modified EBV-CTL had enhanced antitumor activity, while maintaining their antigen-specificity. Although the proliferation of these cytokine gene transduced CTLs remained strictly antigen dependent, clinical application of this approach likely requires the inclusion of a suicide gene to deal with the potential development of T-cell mutants with autonomous growth. We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach.",
author = "Concetta Quintarelli and Barbara Savoldo and Gianpietro Dotti",
year = "2010",
doi = "10.1007/978-1-60761-786-0_8",
language = "English",
volume = "651",
pages = "119--130",
journal = "Methods in Molecular Biology",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Gene therapy to improve function of T cells for adoptive immunotherapy.

AU - Quintarelli, Concetta

AU - Savoldo, Barbara

AU - Dotti, Gianpietro

PY - 2010

Y1 - 2010

N2 - Adoptive immunotherapy with cytotoxic T cells has shown promising clinical results in patients with metastatic melanoma and post-transplant-associated viral infections. However, the antitumor effect of adoptively transferred tumor-specific cytotoxic T lymphocytes (CTLs) is impaired by the limited capacity of these cells to expand within the tumor microenvironment. Administration of interleukin 2 (IL-2) has been used to overcome this limitation, but the systemic toxicity and the expansion of unwanted cells, including regulatory T cells, limit the clinical value of this strategy. To discover whether transgenic expression of lymphokines by the CTLs themselves might overcome these limitations, we evaluated the effects of transgenic expression of IL-2 and IL-15 in our model of Epstein-Barr Virus-specific CTLs (EBV-CTLs). We found that transgenic expression of IL-2 or IL-15 increased the expansion of EBV-CTLs in vitro and that these gene-modified EBV-CTL had enhanced antitumor activity, while maintaining their antigen-specificity. Although the proliferation of these cytokine gene transduced CTLs remained strictly antigen dependent, clinical application of this approach likely requires the inclusion of a suicide gene to deal with the potential development of T-cell mutants with autonomous growth. We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach.

AB - Adoptive immunotherapy with cytotoxic T cells has shown promising clinical results in patients with metastatic melanoma and post-transplant-associated viral infections. However, the antitumor effect of adoptively transferred tumor-specific cytotoxic T lymphocytes (CTLs) is impaired by the limited capacity of these cells to expand within the tumor microenvironment. Administration of interleukin 2 (IL-2) has been used to overcome this limitation, but the systemic toxicity and the expansion of unwanted cells, including regulatory T cells, limit the clinical value of this strategy. To discover whether transgenic expression of lymphokines by the CTLs themselves might overcome these limitations, we evaluated the effects of transgenic expression of IL-2 and IL-15 in our model of Epstein-Barr Virus-specific CTLs (EBV-CTLs). We found that transgenic expression of IL-2 or IL-15 increased the expansion of EBV-CTLs in vitro and that these gene-modified EBV-CTL had enhanced antitumor activity, while maintaining their antigen-specificity. Although the proliferation of these cytokine gene transduced CTLs remained strictly antigen dependent, clinical application of this approach likely requires the inclusion of a suicide gene to deal with the potential development of T-cell mutants with autonomous growth. We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach.

UR - http://www.scopus.com/inward/record.url?scp=78149242955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149242955&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-786-0_8

DO - 10.1007/978-1-60761-786-0_8

M3 - Article

VL - 651

SP - 119

EP - 130

JO - Methods in Molecular Biology

JF - Methods in Molecular Biology

SN - 1064-3745

ER -